Tagged with B

UK Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of Amgen company culture.   Everyone tells you how complicated the UK market is and that is true – it’s one…

Cannabis Canadian medical cannabis company Tilray’s stock surged by over 77 percent in the first three trading days of last week before dropping dramatically by 47.9 percent to close out the week. The US Drug Enforcement Administration’s decision to allow the company to import cannabis into the USA for medical research…

Innovation “Imagine a world where every single ingredient inside every single pharmaceutical you take is traced from start to finish.” We can all agree that the healthcare system in the United States is in dire need of an overhaul. Technological advances propel us into the 21st Century, but the way data…

Hong Kong Wolfgang Niedermark of GIC in Hong Kong, part of the AHK network of German Chambers of Commerce worldwide assesses the business relationship between Germany and Asia and how Hong Kong compares to its regional competitors as an investment destination What is your assessment of the business relationship between Germany and…

Turkey Hasan Ulusoy, chairman of Nobel Ilac, elaborates on his company’s tremendous successes in Turkey and how they have differentiated themselves through early investment in biotechnology and firmly grasping international opportunities. Ulusoy also highlight’s Nobel’s vision for 2023 and their global ambitions. Alongside hospital products, biologicals are the next big opportunity…

Hong Kong Matthew Man, CEO of Hong Kong cold chain monitoring technology specialist Myndar, expounds on the company’s formation, its differentiating factors, and countering resistance to new innovations in the healthcare sector.   How did you identify the niche in the market for your cold chain monitoring technologies? I founded Myndar back…

Regulation In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models, and talks about access to medicine in developing markets.   The innovative pharmaceutical industry seems to be under unprecedented pressure…

UK There is much debate surrounding the potential impact on the UK’s life sciences industry of the country’s decision to leave the European Union. Here, IQVIA analysis posits ‘upside’ and ‘downside’ Brexit scenarios on pharmaceutical market sales and growth in the UK in comparison to a theoretical ‘No Brexit’ scenario. Different…

Algeria Hepatitis C generics brought Beker to fame, but today its director general Rachid Kerrar discloses the new paths the company is exploring, such as new formulations and an increased focus on exports. He also praises the opportunities for business in pharmaceuticals in Algeria.   Rachid, Beker is most famous for…

Algeria Marko Ackermann of the German-Algerian Chamber of Commerce and Industry (AHK) discusses bringing German and Algerian companies together in partnerships, the investment landscape in Algeria, and the opportunities present in the country’s healthcare and life sciences sectors.   How would you describe the capabilities and offering of AHK in Algeria?…

Algeria Mohamed Benali Khoudja, GM for the Francophone Africa cluster at Abbott reveals the rationale behind creating a country cluster, discusses the market for local CMOs in Algeria, and expands on Abbott’s response to the recent import restrictions.   How easy has it been for you to transition from running GSK…

Turkey Prof. Dr. Temel Yilmaz, president of the Turkish Diabetes Foundation, discussed how the disease has made a massive impact in country and what can be done to tackle the issue before it develops further. He also shares how the organization is working to improve the lives of diabetes patients in…